On Friday, biotechnology innovator KelSie Biotech announced that it has closed the first tranche of $5 million in Series A funding to expand its intellectual property portfolio and expand its market presence.
The investment round, led by Salveo Capital, a leading cannabis-focused investment firm, with participation from LA-based Arcadian Capital and other investors, will support the company’s scientific research and market expansion.
“KelSie is delighted to partner with Salveo and our other investors to bring effective and convenient drug and supplement delivery methods to more consumers,” said Cameron Keluche, KelSie Co-Founder. “We are committed to revolutionizing the delivery of cannabinoids and other drugs with superior bioavailability. Having experienced partners like Salveo and Arcadian is invaluable.”
Joining the likes of SC Labs, TREEZ, and numerous other leading cannabis companies that have attracted capital from Salveo and Arcadian, recent investee KelSie Biotech is a play on alternative delivery technologies as consumers demand more choices and different dosages.
“Our consumer brand strategy is focused on investing in companies that truly add value to the consumption experience and have a high degree of commercial scalability. We believe that the KelSie’s core technologies provide a framework for the mainstream adoption of cannabinoid-based medicines,” said Krishnan Varier, Managing Partner of Arcadian Capital Management.
KelSie Biotech’s Technology
KelSie Biotech creates high bioavailability delivery methods for active pharmaceutical ingredients in the medical, nutraceutical, hemp, and marijuana fields. KelSie then licenses its patented and proprietary technologies which are based on novel particle morphology science and include dry-inhaled powder and true sublingual delivery systems.
“We constantly look for new and innovative technology that drives consumption patterns and introduces healthier and more discreet form factors across the pharmaceutical industry,” said Jeffrey Howard, a Managing Partner at Salveo Capital. “We are impressed with KelSie’s strong patented and proprietary technology, including their true sublingual delivery systems with quick onset times.”
Historically, the most common method for administering medications and supplements has been oral or injection. But the gastrointestinal tract degrades the efficacy of pills and liquids before they reach the bloodstream and there are many complications to syringe-based methods. KelSie’s patented breakthrough delivery methods revolutionize drug delivery for a wide range of applications.
Most recently, the technology has been successfully commercialized under the SUM Microdose brand, licensed to Colorado state cannabis operators producing fast-acting, water-soluble CBD/cannabis sublingual tablets.
As SUM Microdose approaches its first successful year of sales in Colorado, the roll-out has begun across other states through licensing to additional operating partners.
A lesser known fact is that the initial KelSie Biotech technology came from the company’s senior advisor Dr. Robert Sievers, Ph.D., who created an inhalable, needle-free measles vaccine that didn’t require refrigeration.
Sievers received a $20 million, 5-year grant funded by the Bill and Melinda Gates Foundation to develop a measles vaccine that could be used effectively in rural regions lacking medical infrastructure. Now, the company’s cutting edge technologies are being deployed in the cannabis industry.
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from The Daily Marijuana Observer